Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

INLYTA for Malignant urinary tract neoplasm: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where INLYTA was used for Malignant urinary tract neoplasm.

Most Reported Side Effects for INLYTA

Side Effect Reports % Deaths Hosp.
Disease progression 97 19.2% 30 10
Diarrhoea 96 19.0% 7 11
Death 75 14.8% 75 4
Fatigue 68 13.4% 3 8
Nausea 45 8.9% 3 5
Renal cancer 45 8.9% 6 4
Dysphonia 40 7.9% 0 5
Decreased appetite 33 6.5% 3 5
Asthenia 29 5.7% 4 8
Hypertension 26 5.1% 1 7
Vomiting 26 5.1% 4 4
Weight decreased 26 5.1% 3 2
Blood pressure increased 22 4.4% 0 3
Constipation 22 4.4% 0 0
Pain in extremity 21 4.2% 1 3

Other Indications for INLYTA

Renal cancer (236) Renal cell carcinoma (71) Metastatic renal cell carcinoma (46) Renal cancer metastatic (22) Neoplasm malignant (15)

Other Drugs Used for Malignant urinary tract neoplasm

BEVACIZUMAB (156) PAZOPANIB (97) ERLOTINIB (75) ATEZOLIZUMAB (73) CABOZANTINIB S-MALATE (31) SUNITINIB MALATE (28) AXITINIB (23) EVEROLIMUS (13) PEMBROLIZUMAB (11) SUTENT (9)

Related Pages

INLYTA Full Profile All Malignant urinary tract neoplasm Drugs INLYTA Demographics INLYTA Timeline